However, the extent of cardiac dysfunction-induced by the inhibitors (Table 1) appeared to be greater in normal compared to diabetic hearts implying that the EGFR/erbB2 pro-survival pathway was significantly impaired in diabetes. The gene discussed is ERBB2; the disease is diabetes mellitus.